Co-receptor chimeric antigen receptor
CoCARs address the challenge of low antigen density in CAR-T therapies by incorporating LCK-binding domains, enhancing T cell activation and persistence, thereby improving the efficacy of CAR-T cell treatments for tumors with low antigen expression.
Patent Information
- Application Number
- JP2025562593
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-27
- Filing Date
- 2024-04-29
- Publication Date
- 2026-05-13
AI Technical Summary
Current CAR-T cell therapies face limitations in efficacy when tumor-associated antigens are expressed at low densities, leading to T cell exhaustion and reduced persistence, particularly with BBz-CARs, which struggle to effectively target and eliminate low-antigen-density tumor cells.
Development of co-receptor chimeric antigen receptors (CoCARs) that incorporate extracellular domains capable of binding LCK or containing LCK, such as CD4, CD8α, CD28, CD3ε, CD44, or CD146 intracellular signaling domains, enhancing T cell activation and persistence by recruiting LCK to CAR synapses, even at low antigen densities.
CoCARs enhance T cell activation and persistence, improving the efficacy of CAR-T cells in targeting and eliminating tumor cells with low antigen expression, reducing relapse and maintaining robust antitumor responses.